AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03865706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Broad-spectrum antibiotics
Description: Standard of care treatment for infections
Study NCT03989908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfludic noodle
Description: In this intervention arm, subjects will be served with noodles made using microfludic technology.
Study NCT03989908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control noodle
Description: In this intervention arm, subjects will be served with normal noodle.
Study NCT04611464 — intervention group
Intervention type: DRUG
Intervention: Misoprostol
Description: Misoprostol is a PGE1 analog
Study NCT02917863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Thyroxine (tablet, per os)
Study NCT02917863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Thyroxine (oral drops, solution)
Study NCT01878006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT01878006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02202681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the duodenum with the OFDI capsule and system
Study NCT00492921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT04591288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation protocol
Description: FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
Study NCT01499862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibion Bionic Leg
Description: A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
Study NCT03191578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUTI®
Description: Administration of RUTI®
Study NCT03191578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study NCT03931343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
Description: Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
Study NCT03931343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
Description: Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
Study NCT03395132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucicort® Lipid cream
Description: The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
Study NCT03395132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fucidin® cream
Description: The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
Study NCT03395132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fucicort® Lipid cream vehicle
Description: The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
Study NCT03395132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone (Lianbang Beisong®) cream
Description: The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
Study NCT02866487 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
Study NCT01268371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element, Boston Scientific Corporation
Description: Everolimus-eluting stent
Study NCT01268371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobori, Terumo Corporation (Japan)
Description: Biolimus-eluting stent with biodegradable polymer
Study NCT02217540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
Study NCT02217540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard protocol
Description: Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
Study NCT02217540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept Mobilisation with Movement
Description: The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
Study NCT01117792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subcutaneous implantable defibrillator (S-ICD) system
Description: implantable defibrillator system
Study NCT00521001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT00521001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT01807702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-Pyruvate 13C-lactate and dichloroacetate
Description: Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
Study NCT00046891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba
Description: Patients will take 120 mg per day (60 mg BID)
Study NCT00046891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 1 tablet BID
Study NCT04349293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
Study NCT04349293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
Study NCT00286611 — intervention group
Intervention type: PROCEDURE
Intervention: Blood and salivary sampling of amifostine
Description: Sampling of blood and saliva to test for amifostine levels.
Study NCT03590197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin 3 mg/ day with Valproate
Study NCT03590197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with Valproate
Study NCT01082640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules
Study NCT01082640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Febuxostat placebo-matching capsules
Study NCT01082640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching capsules
Study NCT00336180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthWise South Africa curriculum
Description: 18 classroom lessons
Study NCT02259790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine fixed-dose combination tablet
Study NCT02259790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02259790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT03026153 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group Oral Survey 1
Description: Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
Study NCT03026153 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Group Oral Survey 2
Description: Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
Study NCT02840162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
Study NCT02840162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00491738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00491738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Oral repeating dose
Study NCT00491738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunitinib
Description: Oral repeating dose
Study NCT00491738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT00301886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Study NCT00301886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronate
Study NCT00301886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT04092387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: 1) Altering the nicotine content of the tobacco research cigarettes
Study NCT02204228 — intervention group
Intervention type: DEVICE
Intervention: TITAN™ Reverse Shoulder System (TRS)
Description: All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
Study NCT04591288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill only protocol
Description: We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
Study NCT01041573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51 Japanese Encephalitis
Description: 6 mcg or 3 mcg im. at day 0 and day 28
Study NCT01041573 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®720
Description: 0.5 ml im. at day 0 and month 7
Study NCT01041573 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: 0.5 ml im. at day 0 and day 56 and month 7
Study NCT03337841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
Study NCT02927223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Study NCT02927223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise treadmill test
Study NCT02832492 — intervention group
Intervention type: BEHAVIORAL
Intervention: pupil near response
Study NCT01341873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo APN FCI
Study NCT01341873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: Undergo APN FCI
Study NCT01341873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01341873 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01341873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01341873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03345212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
Study NCT03069768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mSMART
Description: A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
Study NCT03069768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chantix
Description: For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Study NCT03069768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Study NCT02727114 — intervention group
Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
Study NCT03609229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch
Description: polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
Study NCT03609229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Sacrocolpopexy
Description: * By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction.
Study NCT03609229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Sacrocolpopexy
Description: * By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction.
Study NCT04092387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: Comparing effects of combining RC2 with EC 1 versus EC2
Study NCT01721577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: IGF-1 receptor inhibitor
Study NCT01536288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhodiola crenulata
Description: Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Study NCT01536288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Study NCT03574480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (training in use of a Smartphone application)
Description: The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
Study NCT03574480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (Advice on healthy diet and physical activity recommendations)
Description: Advice on healthy diet and physical activity recommendations
Study NCT03577171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive 300mg QD of ABI-H0731 tablets orally.
Study NCT03577171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC ETV
Description: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
Study NCT03577171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Participants will receive matching QD placebo tablets orally.
Study NCT02666703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
Study NCT02666703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study NCT01941992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMITAL®
Study NCT01941992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachets
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 5 ml administrated intravenously
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Butorphanol tartrate 1 mg i.v.
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Butorphanol Tartrate 2 mg i.v.
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Flurbiprofen Axetil 50 mg i.v.
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Flurbiprofen Axetil 100 mg i.v.
Study NCT00519246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Tramadol Hydrochloride 10 mg i.v.
Study NCT00887445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV341
Description: 5 - 1000mg once daily
Study NCT00887445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo